{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,10]],"date-time":"2026-09-10T19:08:33Z","timestamp":1789067313571,"version":"build-2803163510"},"reference-count":43,"publisher":"Elsevier BV","issue":"7","license":[{"start":{"date-parts":[[2022,7,1]],"date-time":"2022-07-01T00:00:00Z","timestamp":1656633600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,7,1]],"date-time":"2022-07-01T00:00:00Z","timestamp":1656633600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,5,16]],"date-time":"2022-05-16T00:00:00Z","timestamp":1652659200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100019018","name":"Chinese Academy of Medical Sciences Initiative for Innovative Medicine","doi-asserted-by":"publisher","award":["2021-1-I2M-015"],"award-info":[{"award-number":["2021-1-I2M-015"]}],"id":[{"id":"10.13039\/501100019018","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82002451"],"award-info":[{"award-number":["82002451"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100008235","name":"Peking Union Medical College Hospital","doi-asserted-by":"publisher","award":["3332020024"],"award-info":[{"award-number":["3332020024"]}],"id":[{"id":"10.13039\/501100008235","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["jto.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Thoracic Oncology"],"published-print":{"date-parts":[[2022,7]]},"DOI":"10.1016\/j.jtho.2022.04.012","type":"journal-article","created":{"date-parts":[[2022,5,10]],"date-time":"2022-05-10T00:43:25Z","timestamp":1652143405000},"page":"909-920","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":61,"title":["Three-Year Follow-Up of Neoadjuvant Programmed Cell Death Protein-1 Inhibitor (Sintilimab) in NSCLC"],"prefix":"10.1016","volume":"17","author":[{"given":"Fan","family":"Zhang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei","family":"Guo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bolun","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shuhang","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ning","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bin","family":"Qiu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fang","family":"Lv","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liang","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jian","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kang","family":"Shao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qi","family":"Xue","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1888-2622","authenticated-orcid":false,"given":"Shugeng","family":"Gao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jie","family":"He","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jtho.2022.04.012_bib1","first-page":"7","article-title":"Cancer statistics, 2021","volume":"71","author":"Siegel","year":"2021","journal-title":"CA Cancer J Clin"},{"key":"10.1016\/j.jtho.2022.04.012_bib2","first-page":"394","article-title":"Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"68","author":"Bray","year":"2018","journal-title":"CA Cancer J Clin"},{"key":"10.1016\/j.jtho.2022.04.012_bib3","doi-asserted-by":"crossref","first-page":"103951","DOI":"10.1016\/j.ebiom.2022.103951","article-title":"Worldwide burden and epidemiological trends of tracheal, bronchus, and lung cancer: a population-based study","volume":"78","author":"Zhou","year":"2022","journal-title":"EBiomedicine"},{"key":"10.1016\/j.jtho.2022.04.012_bib4","first-page":"115","article-title":"Cancer statistics in China, 2015","volume":"66","author":"Chen","year":"2016","journal-title":"CA Cancer J Clin"},{"key":"10.1016\/j.jtho.2022.04.012_bib5","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1016\/j.jtho.2020.10.155","article-title":"Lung cancer in Republic of China","volume":"16","author":"Luo","year":"2021","journal-title":"J\u00a0Thorac Oncol"},{"key":"10.1016\/j.jtho.2022.04.012_bib6","doi-asserted-by":"crossref","first-page":"610","DOI":"10.1001\/jamaoncol.2016.5829","article-title":"Association of delayed adjuvant chemotherapy with survival after lung cancer surgery","volume":"3","author":"Salazar","year":"2017","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.jtho.2022.04.012_bib7","first-page":"CD011430","article-title":"Adjuvant chemotherapy for resected early-stage non-small cell lung cancer","author":"Burdett","year":"2015","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.jtho.2022.04.012_bib8","doi-asserted-by":"crossref","first-page":"3552","DOI":"10.1200\/JCO.2007.13.9030","article-title":"Lung adjuvant cisplatin evaluation: a pooled analysis by the LACE Collaborative Group","volume":"26","author":"Pignon","year":"2008","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.jtho.2022.04.012_bib9","doi-asserted-by":"crossref","first-page":"1818","DOI":"10.1016\/j.jtho.2018.09.017","article-title":"Current status and future perspectives on neoadjuvant therapy in lung cancer","volume":"13","author":"Blumenthal","year":"2018","journal-title":"J\u00a0Thorac Oncol"},{"key":"10.1016\/j.jtho.2022.04.012_bib10","doi-asserted-by":"crossref","first-page":"1049","DOI":"10.1016\/S0140-6736(15)60294-X","article-title":"Induction chemoradiation in stage IIIA\/N2 non-small-cell lung cancer: a phase 3 randomised trial","volume":"386","author":"Pless","year":"2015","journal-title":"Lancet"},{"key":"10.1016\/j.jtho.2022.04.012_bib11","doi-asserted-by":"crossref","first-page":"924","DOI":"10.1016\/j.athoracsur.2017.09.030","article-title":"Surgical outcomes after neoadjuvant chemotherapy and ipilimumab for non-small cell lung cancer","volume":"105","author":"Yang","year":"2018","journal-title":"Ann Thorac Surg"},{"key":"10.1016\/j.jtho.2022.04.012_bib12","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1200\/JCO.2010.33.7089","article-title":"Randomized phase III study of surgery alone or surgery plus preoperative cisplatin and gemcitabine in stages IB to\u00a0IIIA non-small-cell lung cancer","volume":"30","author":"Scagliotti","year":"2012","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.jtho.2022.04.012_bib13","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1016\/j.lungcan.2020.07.001","article-title":"Efficacy and safety of\u00a0neoadjuvant immunotherapy in resectable nonsmall cell lung cancer: a meta-analysis","volume":"147","author":"Jia","year":"2020","journal-title":"Lung Cancer"},{"key":"10.1016\/j.jtho.2022.04.012_bib14","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1038\/nri.2017.108","article-title":"The diverse functions of the PD1 inhibitory pathway","volume":"18","author":"Sharpe","year":"2018","journal-title":"Nat Rev Immunol"},{"key":"10.1016\/j.jtho.2022.04.012_bib15","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1186\/s12916-016-0623-5","article-title":"Cancer immunotherapy: the beginning of the end of cancer?","volume":"14","author":"Farkona","year":"2016","journal-title":"BMC Med"},{"key":"10.1016\/j.jtho.2022.04.012_bib16","article-title":"Response and outcomes after anti-CTLA4 versus anti-PD1 combined with stereotactic body radiation therapy for metastatic non-small cell lung cancer: retrospective analysis of two single-institution prospective trials","volume":"8","author":"Chen","year":"2020","journal-title":"J\u00a0Immunother Cancer"},{"key":"10.1016\/j.jtho.2022.04.012_bib17","doi-asserted-by":"crossref","first-page":"4592","DOI":"10.1158\/1078-0432.CCR-18-1538","article-title":"Immunotherapy in non-small cell lung cancer: facts and hopes","volume":"25","author":"Doroshow","year":"2019","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.jtho.2022.04.012_bib18","doi-asserted-by":"crossref","first-page":"1976","DOI":"10.1056\/NEJMoa1716078","article-title":"Neoadjuvant PD-1 blockade in resectable lung cancer","volume":"378","author":"Forde","year":"2018","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jtho.2022.04.012_bib19","doi-asserted-by":"crossref","first-page":"e12","DOI":"10.1016\/S2352-3026(18)30192-3","article-title":"Safety and activity of sintilimab in patients with relapsed or refractory classical Hodgkin lymphoma (ORIENT-1): a multicentre, single-arm, phase 2 trial","volume":"6","author":"Shi","year":"2019","journal-title":"Lancet Haematol"},{"key":"10.1016\/j.jtho.2022.04.012_bib20","doi-asserted-by":"crossref","first-page":"816","DOI":"10.1016\/j.jtho.2020.01.017","article-title":"Neoadjuvant PD-1 inhibitor (Sintilimab) in NSCLC","volume":"15","author":"Gao","year":"2020","journal-title":"J\u00a0Thorac Oncol"},{"key":"10.1016\/j.jtho.2022.04.012_bib21","doi-asserted-by":"crossref","first-page":"5604","DOI":"10.21037\/jtd-21-1007","article-title":"Comparison of surgical difficulty in patients with resectable non-small cell lung cancer under different neoadjuvant treatment modes: a retrospective cohort study","volume":"13","author":"Zhang","year":"2021","journal-title":"J\u00a0Thorac Dis"},{"key":"10.1016\/j.jtho.2022.04.012_bib22","doi-asserted-by":"crossref","first-page":"825","DOI":"10.1097\/JTO.0b013e318247504a","article-title":"Histopathologic response criteria predict survival of patients with resected lung cancer after neoadjuvant chemotherapy","volume":"7","author":"Pataer","year":"2012","journal-title":"J\u00a0Thorac Oncol"},{"key":"10.1016\/j.jtho.2022.04.012_bib23","doi-asserted-by":"crossref","first-page":"e42","DOI":"10.1016\/S1470-2045(13)70334-6","article-title":"Pathological response after neoadjuvant chemotherapy in resectable non-small-cell lung cancers: proposal for the use of major pathological response as a surrogate endpoint","volume":"15","author":"Hellmann","year":"2014","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.jtho.2022.04.012_bib24","first-page":"1642","article-title":"A\u00a0comparative study of genetic profiles of key oncogenesis-related genes between primary lesions and matched lymph nodes metastasis in lung cancer","volume":"10","author":"Chen","year":"2019","journal-title":"J\u00a0Cancer"},{"key":"10.1016\/j.jtho.2022.04.012_bib25","doi-asserted-by":"crossref","first-page":"1281","DOI":"10.1016\/j.jtho.2020.05.020","article-title":"Neoadjuvant immunotherapy for NSCLC: current concepts and future approaches","volume":"15","author":"Uprety","year":"2020","journal-title":"J\u00a0Thorac Oncol"},{"key":"10.1016\/j.jtho.2022.04.012_bib26","doi-asserted-by":"crossref","first-page":"1627","DOI":"10.1056\/NEJMoa1507643","article-title":"Nivolumab versus docetaxel in advanced nonsquamous non-small-cell lung cancer","volume":"373","author":"Borghaei","year":"2015","journal-title":"N\u00a0Engl J Med"},{"issue":"suppl 15","key":"10.1016\/j.jtho.2022.04.012_bib27","article-title":"Neoadjuvant atezolizumab in resectable non-small cell lung cancer (NSCLC): initial results from a multicenter study (LCMC3)","volume":"36","author":"Rusch","year":"2018","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.jtho.2022.04.012_bib28","doi-asserted-by":"crossref","first-page":"1413","DOI":"10.1016\/S1470-2045(20)30453-8","article-title":"Neoadjuvant chemotherapy and nivolumab in resectable non-small-cell lung cancer (NADIM): an open-label, multicentre, single-arm, phase 2 trial","volume":"21","author":"Provencio","year":"2020","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.jtho.2022.04.012_bib29","doi-asserted-by":"crossref","first-page":"1344","DOI":"10.1016\/S0140-6736(21)02098-5","article-title":"Adjuvant atezolizumab after adjuvant chemotherapy in resected stage IB-IIIA non-small-cell lung cancer (IMpower010): a randomised, multicentre, open-label, phase 3 trial","volume":"398","author":"Felip","year":"2021","journal-title":"Lancet"},{"key":"10.1016\/j.jtho.2022.04.012_bib30","doi-asserted-by":"crossref","first-page":"1346","DOI":"10.1001\/jamaoncol.2016.1051","article-title":"Treatment of the immune-related adverse effects of immune checkpoint inhibitors: a review","volume":"2","author":"Friedman","year":"2016","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.jtho.2022.04.012_bib31","doi-asserted-by":"crossref","first-page":"1185","DOI":"10.1158\/2326-6066.CIR-15-0102","article-title":"Radiographic profiling of immune-related adverse events in advanced melanoma patients treated with ipilimumab","volume":"3","author":"Tirumani","year":"2015","journal-title":"Cancer Immunol Res"},{"key":"10.1016\/j.jtho.2022.04.012_bib32","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1016\/j.jtho.2017.11.132","article-title":"Stromal PD-L1-positive regulatory T cells and PD-1-positive CD8-positive T cells define the response of different subsets of non-small cell lung cancer to PD-1\/PD-L1 blockade immunotherapy","volume":"13","author":"Wu","year":"2018","journal-title":"J\u00a0Thorac Oncol"},{"key":"10.1016\/j.jtho.2022.04.012_bib33","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1038\/s41588-018-0312-8","article-title":"Tumor mutational load predicts survival after immunotherapy across multiple cancer types","volume":"51","author":"Samstein","year":"2019","journal-title":"Nat Genet"},{"key":"10.1016\/j.jtho.2022.04.012_bib34","doi-asserted-by":"crossref","DOI":"10.1126\/science.aar3593","article-title":"Pan-tumor genomic biomarkers for PD-1 checkpoint blockade-based immunotherapy","volume":"362","author":"Cristescu","year":"2018","journal-title":"Science"},{"key":"10.1016\/j.jtho.2022.04.012_bib35","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1158\/2159-8290.CD-20-0672","article-title":"Somatic HLA class I loss is a widespread mechanism of immune evasion which refines the use of tumor mutational burden as a biomarker of checkpoint inhibitor response","volume":"11","author":"Montesion","year":"2021","journal-title":"Cancer Discov"},{"key":"10.1016\/j.jtho.2022.04.012_bib36","doi-asserted-by":"crossref","first-page":"2093","DOI":"10.1056\/NEJMoa1801946","article-title":"Nivolumab plus ipilimumab in lung cancer with a high tumor mutational burden","volume":"378","author":"Hellmann","year":"2018","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jtho.2022.04.012_bib37","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1200\/JCO.2017.75.3384","article-title":"Molecular determinants of response to anti-programmed cell death (PD)-1 and anti-programmed death-ligand 1 (PD-L1) blockade in patients with non-small-cell lung cancer profiled with targeted next-generation sequencing","volume":"36","author":"Rizvi","year":"2018","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.jtho.2022.04.012_bib38","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1093\/annonc\/mdy495","article-title":"Development of tumor mutation burden as an immunotherapy biomarker: utility for the oncology clinic","volume":"30","author":"Chan","year":"2019","journal-title":"Ann Oncol"},{"issue":"suppl 15","key":"10.1016\/j.jtho.2022.04.012_bib39","article-title":"Neoadjuvant nivolumab (N) or nivolumab plus ipilimumab (NI) for resectable non-small cell lung cancer (NSCLC): clinical and correlative results from the NEOSTAR study","volume":"37","author":"Cascone","year":"2019","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.jtho.2022.04.012_bib40","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1097\/JTO.0b013e31823c5c32","article-title":"Worse disease-free survival in never-smokers with ALK+ lung adenocarcinoma","volume":"7","author":"Yang","year":"2012","journal-title":"J\u00a0Thorac Oncol"},{"key":"10.1016\/j.jtho.2022.04.012_bib41","doi-asserted-by":"crossref","first-page":"1265","DOI":"10.1016\/S1470-2045(21)00333-8","article-title":"Treatment-related adverse events of PD-1 and PD-L1 inhibitor-based combination therapies in clinical trials: a systematic review and meta-analysis","volume":"22","author":"Zhou","year":"2021","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.jtho.2022.04.012_bib42","doi-asserted-by":"crossref","first-page":"1794","DOI":"10.1016\/j.jtho.2019.06.010","article-title":"Clinical activity, tolerability, and long-term follow-up of durvalumab in patients with advanced NSCLC","volume":"14","author":"Antonia","year":"2019","journal-title":"J\u00a0Thorac Oncol"},{"key":"10.1016\/j.jtho.2022.04.012_bib43","doi-asserted-by":"crossref","first-page":"860","DOI":"10.1016\/j.jtho.2020.12.015","article-title":"Four-year survival with durvalumab after chemoradiotherapy in stage III NSCLC-an update from the PACIFIC trial","volume":"16","author":"Faivre-Finn","year":"2021","journal-title":"J\u00a0Thorac Oncol"}],"container-title":["Journal of Thoracic Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1556086422002167?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1556086422002167?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,27]],"date-time":"2025-10-27T10:49:02Z","timestamp":1761562142000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1556086422002167"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,7]]},"references-count":43,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2022,7]]}},"alternative-id":["S1556086422002167"],"URL":"https:\/\/doi.org\/10.1016\/j.jtho.2022.04.012","relation":{},"ISSN":["1556-0864"],"issn-type":[{"value":"1556-0864","type":"print"}],"subject":[],"published":{"date-parts":[[2022,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Three-Year Follow-Up of Neoadjuvant Programmed Cell Death Protein-1 Inhibitor (Sintilimab) in NSCLC","name":"articletitle","label":"Article Title"},{"value":"Journal of Thoracic Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jtho.2022.04.012","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 International Association for the Study of Lung Cancer. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}